A Phase 1 interventional study of BCD101 Low Dose Liquid Formulation and BCD101 High Dose Liquid Formulation in Essential Hypertension, sponsored by Bichedam Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Bichedam Co., Ltd. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Essential Hypertension with a site in Korea, Republic of — 11 open to participants now, 13 under way, 4 of them phase 3. Essential Hypertension · Korea, Republic of.
Among the 99 studies in Essential Hypertension with a site in Korea, Republic of, this one is the 72nd largest by enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2025, is one of 21 in phase 1, and was the 95th registered.
481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →11 of the 99 studies in Essential Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+
Shin Poong Pharmaceutical Co. Ltd. · Sites in Korea, Republic of
Ages 19–75
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 190 across the 86 interventional studies, 3,250 across the 13 observational. Of the 78 that completed or were terminated, 7 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 99 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Bichedam Co., Ltd. as lead sponsor.
Bichedam Co., Ltd. has 1 study filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
3 of the studies in Essential Hypertension with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07373613Boryung Pharmaceutical Co., LtdA Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | 2027-02-01 |
| NCT06282549Yuhan CorporationStudy to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 99 studies in Essential Hypertension with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.
The primary objectives of this study are to determine:
A control group is included, and dose cohorts will be compared to assess dose-dependent differences in safety, tolerability, and pharmacokinetics.
Key study activities include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy adult volunteers aged 19 years or older at screening.
Body weight ≥ 50.0 kg and (BMI) between 18.0 kg/m² and 30.0 kg/m² at screening.
* BMI (kg/m²) = weight (kg) / {height (m)}²
History or current liver, kidney, neurological, psychiatric, respiratory, endocrine, hematological, neoplastic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal disorders.
Clinically significant abnormalities on 12-lead at screening, including:
Clinically significant laboratory abnormalities at screening, including:
Vital signs at screening after at least 3 minutes of rest in a seated position meet any of the following:
Pulse rate ≤ 40 bpm or ≥ 100 bpm
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 Participants in the SAD-1(Treatment group) arm received a single oral dose of BCD101-1(2 sachets). BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.
Drug: BCD101 Low Dose Liquid Formulation
6 Participants in the SAD-2(Treatment group) arm received a single oral dose of BCD101-2(2 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.
Drug: BCD101 High Dose Liquid Formulation
6 Participants in the SAD-3(Treatment group) arm received a single oral dose of BCD101-2(3 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.
Drug: BCD101 High Dose Liquid Formulation
6 Participants in the SAD-4(Treatment group) arm received a single oral dose of BCD101-2(4 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.
Drug: BCD101 High Dose Liquid Formulation
6 Participants in the MAD-1(Treatment group) arm received BCD101-1(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.
Drug: BCD101 Low Dose Liquid Formulation
6 Participants in the MAD-2(Treatment group) arm received BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.
Drug: BCD101 High Dose Liquid Formulation
6 Participants in the MAD-3(Treatment group) arm received a combination of BCD101-1(1 sachet) and BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet, while BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.
Drug: BCD101 Low + High Dose Liquid Formulation
2 Participants in the SAD-1(Placebo group) arm received a single oral dose of BCD101-P(2 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.
Drug: BCD101 Placebo Liquid Formulation
2 Participants in the SAD-2(Placebo group) arm received a single oral dose of BCD101-P(2 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.
Drug: BCD101 Placebo Liquid Formulation
2 Participants in the SAD-3(Placebo group) arm received a single oral dose of BCD101-P(3 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.
Drug: BCD101 Placebo Liquid Formulation
2 Participants in the SAD-4(Placebo group) arm received a single oral dose of BCD101-P(4 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.
Drug: BCD101 Placebo Liquid Formulation
2 Participants in the MAD-1(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.
Drug: BCD101 Placebo Liquid Formulation
2 Participants in the MAD-2(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. The study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.
Drug: BCD101 Placebo Liquid Formulation
2 Participants in the MAD-3(Placebo group) arm received BCD101-P(2 sachets), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to the active formulations, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.
Drug: BCD101 Placebo Liquid Formulation
\[SAD\] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at low concentration. \[MAD\] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at low concentration.
\[SAD\] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration. \[MAD\] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.
\[MAD\] A combination of BCD101-1(2 g) and BCD101-2(4 g) liquid formulations, administered orally as separate sachets simultaneously. Used for multiple dosing.
\[SAD Placebo\] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. \[MAD Placebo\] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.
Number of Participants With Adverse Events (Single-Ascending Dose, SAD)
All adverse events occurring during the clinical trial following a single ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term.
Time frame: Day -1, Day 1, post-study visit (Day 4-7)
Physical Examination Abnormalities (SAD)
A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.
Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Systolic and Diastolic Blood Pressure (SAD)
Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position.
Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Heart Rate (SAD)
Heart rate will be measured after at least three minutes of rest in the seated position.
Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Body Temperature (SAD)
Body temperature will be measured after at least three minutes of rest in the seated position.
Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)
Electrocardiogram (ECG) Abnormalities (SAD)
A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.
Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)
Laboratory Abnormalities (SAD)
Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.
Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)
Number of Participants With Adverse Events (MAD)
All adverse events occurring during the clinical trial following a multiple ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term.
Time frame: Day -1 through Day 7, and post-study visit (Day 8-12)
Physical Examination Abnormalities (MAD)
A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.
Time frame: Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
Vital signs: Systolic and Diastolic Blood Pressure (MAD)
Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position.
Time frame: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Vital signs: Heart Rate (MAD)
Heart rate will be measured after at least three minutes of rest in the seated position.
Time frame: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Vital signs: Body Temperature (MAD)
Body temperature will be measured after at least three minutes of rest in the seated position.
Time frame: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Electrocardiogram (ECG) Abnormalities (MAD)
A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.
Time frame: Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
Laboratory Abnormalities (MAD)
Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.
Time frame: Screening, Day -1, Day 1, Day 6-7, post-study visit (Day 8-12)
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax) (SAD)
Cmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) (SAD)
AUC0-t will be calculated using non-compartmental analysis following a single ascending dose of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) (SAD)
AUCinf will be calculated using non-compartmental analysis from the plasma concentration-time profile following a single ascending dose of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) (SAD)
Tmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Terminal Elimination Half-Life (t1/2) (SAD)
Terminal elimination half-life will be estimated from the terminal phase of the plasma concentration-time profile following a single ascending dose of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Maximum Plasma Concentration at Steady State (Cmax,ss) (MAD)
Cmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameters: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau,ss) (MAD)
AUCtau,ss will be calculated at steady state during multiple ascending dosing (Day 1-7).
Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity at Steady State (AUCinf,ss) (MAD)
AUCinf,ss will be calculated using non-compartmental analysis from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration at Steady State (Tmax,ss) (MAD)
Tmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Terminal Elimination Half-Life at Steady State (t1/2,ss) (MAD)
Terminal elimination half-life at steady state will be estimated from the terminal phase of the plasma concentration-time profile following multiple ascending doses of BCD101.
Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Accumulation Ratio (Rac) (MAD)
Rac will be calculated to assess the accumulation of BCD101 following multiple ascending doses.
Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)
Ran from Sep 2025 to primary completion in May 2026, 7 months.
Of 18 phase 1 interventional studies under Essential Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 7 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2025 → May 2026 and completion Apr 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.